Back to Authors

Dube, John

Mayo Clinic

Division of Oncology Research and Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN.

Citations 2

Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response
Madamsetty, Vijay Sagar , Kiers, Spencer, Alekhina, Olga, Ugolkov, Andrey , Dubé, John J. , Zhang, Yu, Zhang, Jin‐San , Wang, Enfeng , Dutta, Shamit K., Schmitt, Daniel M. , Kozikowski, Alan P. , Mazar, Andrew P. , Billadeau, Daniel D. , Alekhina, Olga , Dube, John, Zhang, Jin-San , Schmitt, Daniel M , Giles, Francis Joseph , Billadeau, Daniel D , Madamsetty, Vijay S , Ding, Li , Dube, John, Mukhopadhyay, Debabrata

Clinical Cancer Research | June 11, 2022 | Volume: 25 | Issue: 21 | Pages: 6452-6462

10.1158/1078-0432.ccr-19-0799 Get It

Abstract Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a predominantly fatal common malignancy with inadequate treatment options. Glycogen synthase kinase 3β (GSK-3β) is an emerging target in human malignancies including PDAC. Experimental Design: Pancreatic cancer cell lines and patient-derived xenografts were treated with a novel GSK-3 inhibitor 9-ING-41 alone or in combination with chemotherapy. Activation of the DNA damage response pathway and S-phase arrest induced by gemcitabine were assessed in pancreatic tumor cells with pharmacologic inhibition or siRNA depletion of GSK-3 kinases by immunoblotting, flow cytometry, and immunofluorescence. Results: 9-ING-41 treatment significantly increased pancreatic tumor cell killing when combined with chemotherapy. Inhibition of GSK-3 by 9-ING-41 prevented gemcitabine-induced S-phase arrest suggesting an impact on the ATR-mediated DNA damage response. Both 9-ING-41 and siRNA depletion of GSK-3 kinases impaired the activation of ATR leading to the phosphorylation and activation of Chk1. Mechanistically, depletion or knockdown of GSK-3 kinases resulted in the degradation of the ATR-interacting protein TopBP1, thus limiting the activation of ATR in response to single-strand DNA damage. Conclusions: These data identify a previously unknown role for GSK-3 kinases in the regulation of the TopBP1/ATR/Chk1 DNA damage response pathway. The data also support the inclusion of patients with PDAC in clinical studies of 9-ING-41 alone and in combination with gemcitabine.
WASH Regulates Glucose Homeostasis by Facilitating Glut2 Receptor Recycling in Pancreatic β-Cells
Han, Lingling , Dubé, John J. , Billadeau, Daniel D. , Dube, John, Billadeau, Daniel D , Ding, Li , Dube, John

Diabetes | November 13, 2018 | Volume: 68 | Issue: 2 | Pages: 377-386

10.2337/db18-0189 Get It

WASH is an endosomal protein belonging to the Wiskott-Aldrich syndrome protein superfamily that participates in endosomal receptor trafficking by facilitating tubule fission via activation of the ubiquitously expressed Arp2/3 complex. While several studies have begun to elucidate an understanding of the functions of WASH in cells lines, the in vivo function of WASH has not been fully elucidated, since total body deletion in mice leads to early embryonic lethality. To circumvent this problem, we have used a WASH conditional knockout mouse model to investigate the role of WASH in the pancreas. We find that pancreas-specific deletion of WASH leads to impaired blood glucose clearance and reduced insulin release upon glucose stimulation. Furthermore, WASH depletion results in impaired trafficking of Glut2 in pancreatic β-cells as a consequence of an intracellular accumulation of Glut2 and overall decreased levels of Glut2 protein. Taken together, these results indicate that WASH participates in pancreatic β-cell glucose sensing and whole-body glucose homeostasis. Thus, patients harboring mutations in components of the WASH complex could be at risk for developing type 2 diabetes.